Loading…

Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant

Background Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by health...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2021-07, Vol.27 (5), p.1261-1264
Main Authors: L Hefler, Jade, M Bailey, Lauren, El Rahi, Cynthia, C Schefler, Amy, Bernicker, Eric H
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663
cites cdi_FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663
container_end_page 1264
container_issue 5
container_start_page 1261
container_title Journal of oncology pharmacy practice
container_volume 27
creator L Hefler, Jade
M Bailey, Lauren
El Rahi, Cynthia
C Schefler, Amy
Bernicker, Eric H
description Background Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by healthcare providers. Immune-related ocular toxicities are rare, but serious adverse events have been reported with the use of checkpoint inhibitors. Case presentation: Here, we describe a rare case of panuveitis during Nivolumab and Ipilimumab combination treatment in a patient being treated for recurrent Small Cell Lung Cancer (SCLC). The patient was managed with an injection of Ozurdex (Allergan, Madison, NJ), a dexamethasone intravitreal implant. The patient had a resolution of inflammation and an improvement in her vision and was able to resume nivolumab monotherapy without recurrence of the panuveitis. Conclusion This case highlights the importance of early recognition of ocular irAEs by ocular oncologists and the successful approach to treatment of immunotherapy-induced panuveitis in order to avoid permanent cessation of therapy.
doi_str_mv 10.1177/1078155220969792
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2455174328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155220969792</sage_id><sourcerecordid>2455174328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663</originalsourceid><addsrcrecordid>eNp1kEFP3DAQhaOqSKXAnaOPvaTYjhM7xwqVgoRUDlTqLZrYk10jx05tZym_gL-No-VUqad5mvfN08xU1SWjXxmT8opRqVjbck77rpc9_1CdMiFlTXv--2PRxa43_1P1OaUnSqmSXJ1Wrw_g1wPabBOxniyQLfpMgid2sc7O6wzjlbeH4DZFdJhH6wtUgClEkmZwrtboHHGr3xENXmMkOSJkNOTZ5j2BkuVzhIPd2o4Y_Asz5j2k4JHYeXHg83l1MoFLePFez6pfN98fr2_r-58_7q6_3de6YSLXggrOtTZj26txEiOH0SjRgMLJdMpQaYyUjSkNLTWnbQu8wWlkQivseNc1Z9WXY-4Sw58VUx5mm7b9wWNY08BF2zIpGq4KSo-ojiGliNOwRDtDfBkYHbafD__-vIzUx5EEOxyewhp9Oeb__BtFi4Ud</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455174328</pqid></control><display><type>article</type><title>Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant</title><source>SAGE</source><creator>L Hefler, Jade ; M Bailey, Lauren ; El Rahi, Cynthia ; C Schefler, Amy ; Bernicker, Eric H</creator><creatorcontrib>L Hefler, Jade ; M Bailey, Lauren ; El Rahi, Cynthia ; C Schefler, Amy ; Bernicker, Eric H</creatorcontrib><description>Background Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by healthcare providers. Immune-related ocular toxicities are rare, but serious adverse events have been reported with the use of checkpoint inhibitors. Case presentation: Here, we describe a rare case of panuveitis during Nivolumab and Ipilimumab combination treatment in a patient being treated for recurrent Small Cell Lung Cancer (SCLC). The patient was managed with an injection of Ozurdex (Allergan, Madison, NJ), a dexamethasone intravitreal implant. The patient had a resolution of inflammation and an improvement in her vision and was able to resume nivolumab monotherapy without recurrence of the panuveitis. Conclusion This case highlights the importance of early recognition of ocular irAEs by ocular oncologists and the successful approach to treatment of immunotherapy-induced panuveitis in order to avoid permanent cessation of therapy.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155220969792</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>Journal of oncology pharmacy practice, 2021-07, Vol.27 (5), p.1261-1264</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663</citedby><cites>FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663</cites><orcidid>0000-0003-0669-2215</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904,79111</link.rule.ids></links><search><creatorcontrib>L Hefler, Jade</creatorcontrib><creatorcontrib>M Bailey, Lauren</creatorcontrib><creatorcontrib>El Rahi, Cynthia</creatorcontrib><creatorcontrib>C Schefler, Amy</creatorcontrib><creatorcontrib>Bernicker, Eric H</creatorcontrib><title>Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant</title><title>Journal of oncology pharmacy practice</title><description>Background Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by healthcare providers. Immune-related ocular toxicities are rare, but serious adverse events have been reported with the use of checkpoint inhibitors. Case presentation: Here, we describe a rare case of panuveitis during Nivolumab and Ipilimumab combination treatment in a patient being treated for recurrent Small Cell Lung Cancer (SCLC). The patient was managed with an injection of Ozurdex (Allergan, Madison, NJ), a dexamethasone intravitreal implant. The patient had a resolution of inflammation and an improvement in her vision and was able to resume nivolumab monotherapy without recurrence of the panuveitis. Conclusion This case highlights the importance of early recognition of ocular irAEs by ocular oncologists and the successful approach to treatment of immunotherapy-induced panuveitis in order to avoid permanent cessation of therapy.</description><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kEFP3DAQhaOqSKXAnaOPvaTYjhM7xwqVgoRUDlTqLZrYk10jx05tZym_gL-No-VUqad5mvfN08xU1SWjXxmT8opRqVjbck77rpc9_1CdMiFlTXv--2PRxa43_1P1OaUnSqmSXJ1Wrw_g1wPabBOxniyQLfpMgid2sc7O6wzjlbeH4DZFdJhH6wtUgClEkmZwrtboHHGr3xENXmMkOSJkNOTZ5j2BkuVzhIPd2o4Y_Asz5j2k4JHYeXHg83l1MoFLePFez6pfN98fr2_r-58_7q6_3de6YSLXggrOtTZj26txEiOH0SjRgMLJdMpQaYyUjSkNLTWnbQu8wWlkQivseNc1Z9WXY-4Sw58VUx5mm7b9wWNY08BF2zIpGq4KSo-ojiGliNOwRDtDfBkYHbafD__-vIzUx5EEOxyewhp9Oeb__BtFi4Ud</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>L Hefler, Jade</creator><creator>M Bailey, Lauren</creator><creator>El Rahi, Cynthia</creator><creator>C Schefler, Amy</creator><creator>Bernicker, Eric H</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0669-2215</orcidid></search><sort><creationdate>202107</creationdate><title>Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant</title><author>L Hefler, Jade ; M Bailey, Lauren ; El Rahi, Cynthia ; C Schefler, Amy ; Bernicker, Eric H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>L Hefler, Jade</creatorcontrib><creatorcontrib>M Bailey, Lauren</creatorcontrib><creatorcontrib>El Rahi, Cynthia</creatorcontrib><creatorcontrib>C Schefler, Amy</creatorcontrib><creatorcontrib>Bernicker, Eric H</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>L Hefler, Jade</au><au>M Bailey, Lauren</au><au>El Rahi, Cynthia</au><au>C Schefler, Amy</au><au>Bernicker, Eric H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><date>2021-07</date><risdate>2021</risdate><volume>27</volume><issue>5</issue><spage>1261</spage><epage>1264</epage><pages>1261-1264</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Background Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by healthcare providers. Immune-related ocular toxicities are rare, but serious adverse events have been reported with the use of checkpoint inhibitors. Case presentation: Here, we describe a rare case of panuveitis during Nivolumab and Ipilimumab combination treatment in a patient being treated for recurrent Small Cell Lung Cancer (SCLC). The patient was managed with an injection of Ozurdex (Allergan, Madison, NJ), a dexamethasone intravitreal implant. The patient had a resolution of inflammation and an improvement in her vision and was able to resume nivolumab monotherapy without recurrence of the panuveitis. Conclusion This case highlights the importance of early recognition of ocular irAEs by ocular oncologists and the successful approach to treatment of immunotherapy-induced panuveitis in order to avoid permanent cessation of therapy.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/1078155220969792</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0669-2215</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-1552
ispartof Journal of oncology pharmacy practice, 2021-07, Vol.27 (5), p.1261-1264
issn 1078-1552
1477-092X
language eng
recordid cdi_proquest_miscellaneous_2455174328
source SAGE
title Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T22%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Panuveitis%20in%20patient%20on%20ipilimumab/nivolumab%20combination%20for%20small-cell%20lung%20cancer%20treated%20with%20an%20intravitreal%20dexamethasone%20implant&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=L%20Hefler,%20Jade&rft.date=2021-07&rft.volume=27&rft.issue=5&rft.spage=1261&rft.epage=1264&rft.pages=1261-1264&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155220969792&rft_dat=%3Cproquest_cross%3E2455174328%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c314t-40422ccdb598bf4b2abd843a8efd68d07dd773d3a8c7c2055a23efb14c8e62663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2455174328&rft_id=info:pmid/&rft_sage_id=10.1177_1078155220969792&rfr_iscdi=true